Emcure Pharmaceuticals board meeting scheduled for May 5, 2026 to approve audited standalone and consolidated financial results for Q4 and FY26.
Board will consider recommending a final dividend for the financial year ended March 31, 2026.
Trading window for designated persons is closed from April 1 until May 7, 2026, as per insider trading regulations.